Exploring the Ticagrelor-Statin Interplay in the PLATO Trial

Publisher： Karger

E-ISSN： 1421-9751|124|2|105-107

ISSN： 0008-6312

Source： Cardiology, Vol.124, Iss.2, 2013-02, pp. : 105-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent

By  

Cardiology, Vol. 120, Iss. 3, 2012-01 ,pp. : 169-171

Karger

Access to resources Recommend Favorite

Aspirin Dose and Ticagrelor Benefit in PLATO: Fact or Fiction?

By  

Cardiology, Vol. 117, Iss. 4, 2011-02 ,pp. : 280-283

Karger

Access to resources Recommend Favorite

Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor

By  

Cardiology, Vol. 117, Iss. 3, 2011-01 ,pp. : 231-233

Karger

Access to resources Recommend Favorite

Ticagrelor

By  

PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol. 33, Iss. 7, 2016-09 ,pp. : 258-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of Statistical Heterogeneity in the PLATO Trial

By  

Cardiology, Vol. 118, Iss. 2, 2011-05 ,pp. : 138-138

Karger

Access to resources Recommend Favorite